Healios K.K (HLOSF PINK) stock market data APIs
$2.2463
0(0%)
as of May 15, 2025
Try our APIs with
free plan!
Healios K.K Financial Data Overview
Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company develops HLCM051, which is preparing for phase 3 clinical trial, as well as preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is in phase 2/3 and phase 3 clinical trial to treat ischemic stroke; and HLCM051, which is in phase 2 clinical trial to treat trauma. It also develops HLCR011, which is in phase 1/2 clinical trial for the treatment of retinal pigmen epithelium and age-related macular degeneration; and HLCN061, which is in discovery and preclinical trial for treating solid tumors. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.
Prev. Close
2.2463
Open
2.2463
High
2.2463
Low
2.2463
52 wk Range
0.9258-2.42
Market Cap
228 M
Shares Outstanding
101 M
Revenue
560 M
EPS
-0.1753
Beta
1.256
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Healios K.K data using free add-ons & libraries
Get Healios K.K Fundamental Data
Healios K.K Fundamental data includes:
- Net Revenue: 560 M
- EBITDA: -2 551 000 064
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-31
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Healios K.K News
New
Athersys and Healios K.K. Announce Advancement of Their MultiStem Commercial Partnership
Improvements to Collaboration Enhance Preparations for Commercial Activity in Japan CLEVELAND & TOKYO, August 05, 2021--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX) and HEALIOS K.K. (Healios) (TSE ...
Healios Successfully Establishes Proprietary Universal Donor Cell Research Line
TOKYO, June 5, 2020 /PRNewswire/ -- Healios K.K. (hereinafter "the Company"; TSE: 4593), Japan's leading clinical-stage biotechnology company, has been creating Universal Donor Cells (UDCs), which are...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
